Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023

Rhea-AI Summary

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will announce its 2023 first quarter financial results on May 10, 2023, after U.S. market close. The management will host a live audio webcast at 4:30 p.m. ET to discuss the financial results and provide updates on the business. Interested parties can register for the call in advance via the company’s website. A replay of the webcast will also be available subsequently.

Jazz Pharmaceuticals is focused on developing innovative treatments for serious diseases, with a robust portfolio that includes marketed medicines and novel products across neuroscience and oncology. The company operates globally, serving patients in nearly 75 countries. For more details, visit www.jazzpharmaceuticals.com.

Positive

• Jazz Pharmaceuticals is preparing to report Q1 2023 results on May 10, indicating ongoing financial activity.
• The scheduled live webcast will provide insights into the company's financial performance and business updates.

Negative

• None.

DUBLIN, April 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 first quarter financial results on Wednesday, May 10, 2023, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2023 first quarter financial results and provide a business and financial update.  

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. 

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.

Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2023-first-quarter-financial-results-on-may-10-2023-301807430.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When will Jazz Pharmaceuticals report its Q1 2023 financial results?

Jazz Pharmaceuticals will report its Q1 2023 financial results on May 10, 2023.

What time is the Jazz Pharmaceuticals Q1 2023 results webcast?

The webcast for Jazz Pharmaceuticals Q1 2023 results will take place at 4:30 p.m. ET.

How can I listen to the Jazz Pharmaceuticals Q1 2023 earnings call?

You can register for the Jazz Pharmaceuticals Q1 2023 earnings call through their website.

Where can I find the replay of the Jazz Pharmaceuticals earnings call?

A replay of the Jazz Pharmaceuticals earnings call will be available on their Investors section of the website.